Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Bristol-Myers Squibb
Bristol-Myers Squibb
BioNTech SE
Bristol-Myers Squibb
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Hoffmann-La Roche
AbbVie
Hoffmann-La Roche
Second Affiliated Hospital of Nanchang University
Eikon Therapeutics
Regeneron Pharmaceuticals
Shanghai Henlius Biotech
Shanghai Shengdi Pharmaceutical Co., Ltd
Polaris Group
Canadian Cancer Trials Group
Taizhou Hanzhong biomedical co. LTD
Canadian Cancer Trials Group
Transgene
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
Hamamatsu University
Charite University, Berlin, Germany